Cytori Therapeutics Inc (NASDAQ:CYTX) received a $5.00 price target from investment analysts at Maxim Group in a note issued to investors on Monday. The firm currently has a “buy” rating on the biotechnology company’s stock.
The analysts wrote, “Cytori presented data in Ovarian Cancer at the 2017 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting demonstrating bioequivalence of ATI-0918, generic liposomal formulation of doxorubicin, to J&Js CAELYX (branded EU product). We expect Cytori to file for approval in Europe in 2H18 and the company to partner ATI-0918 for commercialization. We profile the opportunity for liposomal doxorubicin, which was acquired with the acquisition of Azaya earlier in 2017, in the attachment below.””
A number of other research analysts have also recently commented on CYTX. B. Riley restated a “neutral” rating on shares of Cytori Therapeutics in a research report on Wednesday, August 16th. Zacks Investment Research cut Cytori Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. Finally, ValuEngine cut Cytori Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 1st.
Cytori Therapeutics (NASDAQ CYTX) traded up $0.02 during mid-day trading on Monday, reaching $0.36. The company’s stock had a trading volume of 317,216 shares, compared to its average volume of 770,576. Cytori Therapeutics has a 1 year low of $0.28 and a 1 year high of $2.13.
Cytori Therapeutics (NASDAQ:CYTX) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.02. The firm had revenue of $1.77 million for the quarter, compared to analysts’ expectations of $2.04 million. Cytori Therapeutics had a negative return on equity of 228.21% and a negative net margin of 367.33%. During the same quarter last year, the business earned ($0.26) EPS. sell-side analysts forecast that Cytori Therapeutics will post -0.62 earnings per share for the current fiscal year.
WARNING: “Maxim Group Analysts Give Cytori Therapeutics Inc (CYTX) a $5.00 Price Target” was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://sportsperspectives.com/2017/11/14/cytori-therapeutics-inc-cytx-given-a-5-00-price-target-by-maxim-group-analysts.html.
Several hedge funds and other institutional investors have recently modified their holdings of CYTX. Vanguard Group Inc. boosted its stake in Cytori Therapeutics by 81.9% in the second quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock valued at $674,000 after buying an additional 275,653 shares in the last quarter. Perkins Capital Management Inc. boosted its stake in Cytori Therapeutics by 99.0% in the second quarter. Perkins Capital Management Inc. now owns 874,896 shares of the biotechnology company’s stock valued at $962,000 after buying an additional 435,217 shares in the last quarter. Finally, Sabby Management LLC boosted its stake in Cytori Therapeutics by 28.0% in the second quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock valued at $1,789,000 after buying an additional 355,504 shares in the last quarter. Institutional investors own 12.02% of the company’s stock.
About Cytori Therapeutics
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.